ClinicalTrials.gg
RecruitingNCT06466525Updated Sep 25, 2026

A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.

A Phase 1 interventional study of LBT-3627 and Placebo in Parkinson Disease, sponsored by Longevity Biotech Australia Pty Ltd (subsidiary). Recruiting at 3 sites in Australia. Open to participants aged 30 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Longevity Biotech Australia Pty Ltd (subsidiary) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Sep 25, 2026Study contact changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
30 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Parkinson Disease with a site in Australia — 10 open to participants now, 12 under way, 3 of them phase 3. Parkinson Disease · Australia.

Planned enrollment
40th of 54
64 · median 132
Started
2024
with 3 others
Phase 1
8 of 59
4 open now
Primary completion
2027-02
later than 5 of 11 live
Registered
51st of 59
by date

Among the 59 studies in Parkinson Disease with a site in Australia, this one is the 40th largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2024, is one of 8 in phase 1, reaches primary completion later than 5 of the 11 other live ones, and was the 51st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

10 of the 59 studies in Parkinson Disease with a site in Australia are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 89 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Parkinson Disease with a site in Australia, or all of them as a file.
02

Study summary

Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.

Read the detailed description

Evaluate the safety and tolerability of LBT-3627 in both a single and multiple ascending dose study.

Phase Ia will explore safety and tolerability first in healthy volunteers then followed by Parkinson's patients after a single dose. Dose levels will escalate per cohort.

Phase Ib will explore safety and tolerability in Parkinson's patients after multiple doses. Dose levels will escalate per cohort.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Both cohorts (Healthy Volunteers and Parkinson's Disease)

Key inclusion criteria

  • Male or female, 30-89 years inclusive at screening
  • 18-32 kg/m²
  • Vital signs, ( \<450 ms male / \<470 ms female), and safety labs without abnormality; no orthostatic hypotension
  • Women of non-, or using highly effective per protocol

Key exclusion criteria

  • Immunomodulators / - HV: any (incl. OTC) within 90 days; PD: systemic within 60 days and topical/nasal-inhaled OTC within 7 days (both waivable only with Sponsor approval)
  • Vaccine within 60 days (HV) / 45 days (PD) of first dose
  • CoQ10 within 5 days
  • Inadequate renal function ( ≤ 60 mL/min; ≤ 79 if HV under 40), or LFTs / > 1.5×
  • Clinically significant cardiovascular, hepatic, renal, neurological, or psychiatric disease
  • Active infection requiring systemic anti-infectives within 14 days; positive // serology

Parkinson's Disease participants - additional key inclusion criteria

  • PD diagnosis by a neurologist/geriatrician, 6 months to \< 11 years before first dose, per MDS clinical diagnostic criteria
  • Hoehn \& Yahr stage 1-3
  • If on levodopa: stable ≥ 2 months and able to withhold ≥ 12 hours (overnight) around dosing/assessments; if not, remain treatment-naïve through end of study

Parkinson's Disease participants - additional key exclusion criteria

  • Prior PD brain surgery, focused ultrasound, or neuromodulation; no anti-amyloid/anti-tau biologics
  • Antibiotics within 30 days; OTC pre/probiotics; ≥ 3 unexplained falls in 12 months

Note: Additional protocol-defined criteria apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Healthy Volunteers - SAD

    Single dose of LBT-3627 administered to healthy volunteers

    Drug: LBT-3627 · Drug: Placebo

  • Experimental
    Parkinson's disease patients - SAD

    Single dose of LBT-3627 administered to Parkinson's disease patients

    Drug: LBT-3627 · Drug: Placebo

  • Experimental
    Parkinson's disease patients - MAD

    Multiple doses of LBT-3627 administered to Parkinson's disease patients

    Drug: LBT-3627 · Drug: Placebo

Interventions

  • DrugLBT-3627

    Synthetic peptide

  • DrugPlacebo

    Vehicle

06

What researchers measure

Primary outcomes

  1. Incidence, nature, and severity of adverse events [Safety and Tolerability]

    Time frame: Day of treatment to end of follow-up period (1, 2 or 4 weeks)

Secondary outcomes

  1. Maximum Plasma Concentration [Cmax]

    The peak plasma concentration of a drug after administration.

    Time frame: Day of treatment to end of follow-up period (1, 2 or 4 weeks)

  2. Elimination half life [T1/2]

    The time required for the concentration of the drug to reach half of its original value.

    Time frame: Day of treatment to end of follow-up period (1, 2 or 4 weeks)

  3. Time to reach Cmax [Tmax]

    Time required to reach Cmax.

    Time frame: Day of treatment to end of follow-up period (1, 2 or 4 weeks)

  4. Volume of Distribution [Vd]

    The apparent volume in which a drug is distributed (i.e., the parameter relating drug concentration in plasma to drug amount in the body).

    Time frame: Day of treatment to end of follow-up period (1, 2 or 4 weeks)

  5. Concentration [C]

    Amount of drug in a given volume of plasma

    Time frame: Day of treatment to end of follow-up period (1, 2 or 4 weeks)

  6. Area under the curve [AUC]

    The integral of the concentration-time curve (after a single dose or in steady state).

    Time frame: Day of treatment to end of follow-up period (1, 2 or 4 weeks)

  7. Clearance [CL]

    The volume of plasma cleared of the drug per unit time.

    Time frame: Day of treatment to end of follow-up period (1, 2 or 4 weeks)

  8. Bioavailability [f]

    The systemically available fraction of a drug.

    Time frame: Day of treatment to end of follow-up period (1, 2 or 4 weeks)

07

Study locations

2 of 3 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Feb 2027, 31 months after the start.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 31 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 20, 2024
StartActual
Jul 16, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Monash Medical Center · Melbourne, Australia
Sep 25, 2026
Contact
Study contact changed: T•••@avancecro.com · •••2172→k•••@alfred.org.au · •••1448. See the current contact
Sep 25, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Alfred Hospital · Melbourne, AustraliaContact N•••@alfred.org.au · •••1448→B•••@alfred.org.au · •••1448
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    1 site added
    Show site
    • Monash Medical Center · Melbourne, Australia
    Contact Study contact changed: T•••@avancecro.com · •••2172→k•••@alfred.org.au · •••1448. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Alfred Hospital · Melbourne, AustraliaContact N•••@alfred.org.au · •••1448→B•••@alfred.org.au · •••1448
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06466525
Lead sponsor
Longevity Biotech Australia Pty Ltd (subsidiary)
Responsible party
Sponsor
First posted
Jun 20, 2024
Start date
Jul 16, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Kelly Bertram, MD
Contact
k.bertram@alfred.org.au
+61 0487 531 448

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion